Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Men's Health

Men's Health

Recruiting

Prostate cancer support from a peer

TrueNTH (True North) Peer Navigation is a new study that puts trained prostate cancer survivors and caregivers in touch with patients and caregivers looking for support. Peer navigators will help prostate cancer patients and caregivers navigate their journey through cancer care, from the point of diagnosis to treatment and beyond and will provide emotional, practical, and informational support. This work was awarded by Prostate Cancer Canada and is proudly funded by the Movember Foundation.

Status
Recruiting
Principal Investigator
Arminee Kazanjian
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
19 and above

Feasibility of using the ARES Device to measure sleep in men with prostate cancer starting androgen deprivation therapy

The primary purpose of our study is to examine the feasibility of using the ARESTM device to measure sleep parameters of PCa patients who are on ADT. In addition, we will also assess the feasibility of obtaining serial questionnaires from patients. In this small pilot study, we will describe subjective sleep quality, morphometric measures, urinary symptoms, hot flashes, and weight gain.

Recruitment Poster

Status
Recruiting
Principal Investigator
Larry Goldenberg
Body Locations and Systems
Prostate Cancer
Area
Vancouver

PC 360 Survivorship

Prostate Cancer Survivorship 360º is a collaboration-based initiative involving prostate cancer (PC) and survivorship researchers/clinicians from three Canadian prostate centers with the goal of identifying and tracking unmet supportive care needs of patients with localized PC and responding to these needs through survivorship care. The current randomized control trail (RCT) will focus on the development and evaluation of a facilitated electronic Prostate Cancer Survivorship Care Plan (PC-SCP).

Status
Recruiting
Principal Investigator
Larry Goldenberg
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer (proSPECT-AS)

99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and / or are candidates for active surveillance, but have planned to undergo radical prostatectomy. In these patients, the results may be used to help estimate the risk of a histopathologic Gleason grade of > 3+4. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 to detect clinically significant prostate cancer when compared to histopathology.

Status
Recruiting
Principal Investigator
Philip Cohen
Body Locations and Systems
Prostate Cancer
Area
Various sites
Age
18 and above

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.

Status
Recruiting
Principal Investigator
Martin Gleave
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)

The purpose of this study is to determine if the addition of JNJ-56021927 to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with low volume mHSPC.

Status
Recruiting
Principal Investigator
Kim Nguyen Chi
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

The goal of this clinical research study is to learn if treatment with standard systemic therapy in combination with surgery or radiation therapy is more effective at controlling prostate cancer than standard systemic therapy alone. The safety of this treatment combination will also be studied.

Status
Recruiting
Principal Investigator
Martin Gleave
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Status
Recruiting
Principal Investigator
Martin Gleave
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Prostate Cancer (EMMPC)

The investigators aim to evaluate the feasibility of a larger clinical trial assessing an exercise program during the "teachable moment" in patients with prostate cancer and measuring its effect on tumor apoptosis signaling, lipogenesis and steroidogenesis. Participants will be randomized between a 8-12 week exercise program or to standard of care only. Participants will be assessed at screening, baseline (day 0), throughout the trial intervention (days 1-84), post-intervention visit (prior to radical prostatectomy) and final study visit 6-months post-radical prostatectomy.

Status
Recruiting
Principal Investigator
Peter Black
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
19 and above

Etiology Study of Prostatitis

Prostatitis is so widespread a disease that affects people from youths to seniors, with approximately a third experiencing a remission of symptoms over a year follow-up. Although the etiology of prostatitis is still not clear, it is mainly thought to be due to infection of bacteria or other microorganisms. Up to now, there is still no research being done on the microbiome (bacterial species) of the prostate. The objective of this study is to look at the etiology of chronic prostatitis (bacteria or non-bacteria prostatitis), mainly focusing on the effect of bacteria in the prostate.

Status
Recruiting
Principal Investigator
Ben Chew
Body Locations and Systems
Prostate Diseases
Area
Vancouver
Age
19 and above

Closed for Recruitment

Sexual Recovery After Prostate Cancer

We are conducting a study in order to prospectively track the sexual outcomes of men after their prostate cancer treatment. 

Status
Closed for Recruitment
Principal Investigator
Peter Black
Body Locations and Systems
Sexual Health
Prostate Cancer
Area
Vancouver

Active Surveillance Genetic Sampling Study

To collect saliva samples from men who are currently or were previously on active surveillance to try and identify genetic factors that could suggest how aggressive their prostate cancer could be. This is part of a larger study led by Dr. William Catalona at Northwestern University, Chicago. 

Status
Closed for Recruitment
Principal Investigator
Larry Goldenberg
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to compare the radiographic progression-free survival (rPFS) of JNJ56021927 in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).

Status
Closed for Recruitment
Principal Investigator
Martin Gleave
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate and low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).


 

Status
Closed for Recruitment
Principal Investigator
Kim Nguyen Chi
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

Increasing healthy outcomes for prostate cancer survivors: An innovative cooking class intervention feasibility study

The purpose of the study is to test the impact of a novel intervention to promote healthy nutrition and weight control for prostate cancer survivors and their partners

Status
Closed for Recruitment
Principal Investigator
Carolyn Gotay
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

The purpose of this study is to evaluate the efficacy and safety of ARN-509 in adult men with high-risk non-metastatic castration-resistant prostate cancer.


Status
Closed for Recruitment
Principal Investigator
Martin Gleave
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

Focal Therapy for Prostate Cancer - A Pilot Study of Focal Low Dose Rate Brachytherapy (FTPC)

This project will develop and evaluate a treatment plan for prostate focal therapy based on low dose rate brachytherapy. The participants entering this study are those suitable for active surveillance. These participants will be monitored with various imaging methods and interventions such as MR elastography, Transrectal ultrasound elastography, PET/CT and transperineal mapping biopsy to determine the extent of cancer and suitable treatments.

Status
Closed for Recruitment
Principal Investigator
William J. Morris
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above
Subscribe to Men's Health

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy